Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Rapid Infusion of Obinutuzumab in B-cell Non-Hodgkin's Lymphoma
NCT05510219Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
obinutuzumab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT05510219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05510219.